Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Faten Madani"'
Publikováno v:
Pharmaceutical Development and Technology
Pharmaceutical Development and Technology, Taylor & Francis, In press, 25 (2), pp.133-148. ⟨10.1080/10837450.2019.1689402⟩
Pharmaceutical Development and Technology, Taylor & Francis, In press, 25 (2), pp.133-148. ⟨10.1080/10837450.2019.1689402⟩
International audience; Most of biopharmaceuticals in clinical use today are available in a solution or suspension form and delivered by invasive routes (i.e. injection). However, several attempts have been made in order to develop effective oral for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2923ef318105f7bba81ae1e5a4272328
http://hdl.handle.net/20.500.12278/3854
http://hdl.handle.net/20.500.12278/3854
Publikováno v:
Research Journal of Pharmacy and Technology. 10:3271
The objective of this study is to prepare Paracetamol Microcapsules using Gelatin type A and Gum Arabic as a hydrophilic polymers. Microcapsules were prepared by complex Coacervation. Microencapsulation Yield “MEY” and microencapsulation efficien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54b8d4fc839def426d4442743d22d23e
https://doi.org/10.5958/0974-360x.2017.00580.7
https://doi.org/10.5958/0974-360x.2017.00580.7
Autor:
Jean-Claude Chaumeil, Faten Madani
Publikováno v:
Journal of microencapsulation. 25(2)
Indomethacin-loaded dietheylaminoethyl trisacryl microspheres (DEAE-MS), originally designed for therapeutic embolization, were encapsulated using two methods: coacervation and solvent evaporation/extraction. This encapsulation was achieved using a b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9614eb5cb8a1a1c0474b5b1df4242be
https://pubmed.ncbi.nlm.nih.gov/18246490
https://pubmed.ncbi.nlm.nih.gov/18246490
Publikováno v:
Research Journal of Pharmacy and Technology. 8:161
Methyldopa, an anti-hypertensive drug having a half life of less than 2 hours, and given with a dose of 250 mg 3–4 times daily.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65803ed8e9de811072f8c222d59e0f88
https://doi.org/10.5958/0974-360x.2015.00029.3
https://doi.org/10.5958/0974-360x.2015.00029.3
Autor:
Amina Lakrouf, Christine Vauthier, Daniel Scherman, Jean-Claude Chaumeil, Michel Bessodes, Faten Madani
Publikováno v:
Biomaterials
Biomaterials, Elsevier, 2007, 28 (6), pp.1198-208. 〈10.1016/j.biomaterials.2006.10.017〉
Biomaterials, Elsevier, 2007, 28 (6), pp.1198-208. ⟨10.1016/j.biomaterials.2006.10.017⟩
Biomaterials, 2007, 28 (6), pp.1198-208. ⟨10.1016/j.biomaterials.2006.10.017⟩
Biomaterials, Elsevier, 2007, 28 (6), pp.1198-208. 〈10.1016/j.biomaterials.2006.10.017〉
Biomaterials, Elsevier, 2007, 28 (6), pp.1198-208. ⟨10.1016/j.biomaterials.2006.10.017⟩
Biomaterials, 2007, 28 (6), pp.1198-208. ⟨10.1016/j.biomaterials.2006.10.017⟩
International audience; In this study, microspheres designed for embolization, defined as GF2000-Trisacryl MS (GF-MS) and DEAE-Trisacryl MS (DEAE-MS), were originally PEGylated using (3-amino propyl) triethoxy silane as coupling agent. Indomethacin w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb8a27b67760b374e244c4a0a9940166
https://pubmed.ncbi.nlm.nih.gov/17113637
https://pubmed.ncbi.nlm.nih.gov/17113637